A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis

Launched by PFIZER · Mar 10, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a medication called etrasimod to see how safe and effective it is for treating moderately to severely active ulcerative colitis in adolescents aged 12 to under 18 years. Ulcerative colitis is a condition that causes inflammation in the intestines, leading to symptoms like stomach pain and diarrhea. The trial is open to adolescents who have been diagnosed with this condition, even if they are currently on certain other treatments. However, it excludes those with more severe forms of colitis or other specific gastrointestinal diseases.

Participants in the trial will undergo treatment for 52 weeks, and those who complete this period may have the chance to continue receiving treatment for up to four additional years. The study is currently recruiting participants of all genders, and it provides a unique opportunity to help researchers learn more about this medication while potentially benefiting from its treatment. If you are considering participating, it’s a good idea to talk to your doctor to see if you might be a good fit for the study.

Gender

ALL

Eligibility criteria

• Inclusion criteria:
• • Have a diagnosis of ulcerative colitis (UC) that is moderately to severely active
• • Participants are permitted to be receiving a therapeutic dose of select UC therapies
• Exclusion criteria:
• • Severe extensive colitis
• • Diagnosis of Crohn's disease (CD) or indeterminate colitis or the presence or history of a fistula consistent with CD
• • Diagnosis of microscopic colitis, ischemic colitis, or infectious colitis